Primitive myxoid mesenchymal tumor of infancy (PMMTI) is a rare tumor with <20 cases reported to date. Recently PMMTI tumors have been found to harbor BCOR internal tandem duplication (ITD), the same genetic alteration detected in clear cell sarcoma of the kidney (CCSK). Complete surgical resection of PMMTI is often curative, but no standard of care has been established for unresectable tumors. We describe a female patient who presented at 13 months of age with a paraspinal mass and spinal cord compression. Histology was consistent with PMMTI, and the tumor was found to harbor BCOR ITD. The patient experienced disease recurrences after multiple surgical resections. After failing to respond to vincristine and actinomycin therapy, the patient demonstrated a nearly complete response to a doxorubicin-containing chemotherapy regimen. The patient's therapy was consolidated with proton beam radiotherapy, and she has remained in remission for >12 months after the conclusion of therapy. This case confirms BCOR ITD as a key finding in PMMTI. The therapeutic approach described here is similar to that used for CCSK and provides a model for the treatment of PMMTI not amenable to complete surgical resection.
Primitive myxoid mesenchymal tumor of infancy (PM-MTI) is a rare fibroblastic-myofibroblastic malignancy that typically arises in the first year of life. Alaggio et al 1 originally described PMMTI as being characterized by primitive spindle, polygonal, and round cells in a myxoid background with positive vimentin staining immunohistochemically, but negative for smooth muscle actin, muscle specific actin, desmin, myogenin, and S100 expression. Recently, internal tandem duplication (ITD) of BCOR has been detected in PMMTI, 2 a molecular alteration identical to the hallmark feature found in most clear cell sarcoma of the kidney tumors (CCSK). [3] [4] [5] [6] The clinical course of PMMTI is often No chemotherapy regimen has been established as a reliably effective standard of care for unresectable PMMTI tumors. Importantly, most patients with PMMTI with clinical follow-up reported to date (n=19) were described as alive with disease (n=10), dead of disease (n=1), or dead with disease (n=1) at most recent follow-up. Hence, the morbidity and mortality of this rare tumor type in young children is potentially immense. 2, 7 This report describes an infant with a recurrent PMMTI with confirmed BCOR ITD that responded completely to multiagent chemotherapy, similar to regimens used successfully for CCSK.
Methodology/Results
A 13-month-old girl presented with progressive lower extremity weakness and bladder dysfunction. MRI revealed an epidural lesion extending from L3 to S2 level. The lesion showed low T1 and high T2 signal without contrast enhancement, suggesting a cystic lesion with neural foraminal extension. Initial radiologic diagnosis was an epidural arachnoid cyst (Figures 1 and 2) . The patient underwent an L4 to L5 laminectomy with attempted total resection. Microscopically, the mass demonstrated a cellular neoplasm composed of undifferentiated-appearing stellate to epithelioid cells in an abundant myxoid matrix that stained diffusely positive for CD10 and vimentin, and weakly positive for bcl-2. These histologic findings were consistent with the diagnosis of PMMTI (Figure 3 ). Positive surgical margins were noted. Next-generation sequencing of the tumor revealed BCOR ITD as evidenced by a 30 amino acid in-frame duplicated sequence (S1705_S1706). 8 Also identified was a mutation (Y325*) of CD36, which encodes a thrombospondin receptor and other genetic variations of unknown significance.
Two months after the initial diagnosis, a routine MRI revealed recurrence of the lumbar epidural mass. Over a 6-month period, the patient underwent 2 additional surgeries with positive microscopic margins; however, the tumor recurred within 8 weeks after each surgery. Due to the refractory nature of this tumor, the patient received 2 cycles of a chemotherapeutic regimen consisting of vincristine (0.05 mg/kg/dose) and actinomycin (0.045 mg/kg/dose); however, MRI revealed continued tumor progression increasing from 0.8 x 0.4 cm to 1.4 x 1.0 cm. At the age of 23 months, the patient then began vincristine (1.5 mg/m 2 ), doxorubicin (37.5 mg/m 2 /dose x 2 days), and cyclophosphamide (1,200 mg/m 2 ; VDC) therapy alternating with ifosfamide (1,800 mg/m 2 / dose x 5 days) and etoposide (100 mg/m 2 /dose x 5 days; IE) on a 3-week interval. Imaging was performed after 2 courses of therapy (VDC and IE each given twice), with no discrete mass visible. The patient ultimately received a total of 3 courses each of VDC and IE. Therapy was consolidated with proton beam radiotherapy (RT) delivered in 2 phases, with the standard risk volume receiving 45 cobalt gray equivalent (CGE) and the volume deemed to be at highest risk receiving a total of 64.8 CGE using a 3-field, 3-dimensional conformal proton plan. Special accommodations were used to ensure that the adjacent vertebral bodies received a uniform dose of 23.4 CGE to prevent growth asymmetry. The patient was documented to remain free of disease 12 months after completing therapy.
Discussion
The clinical features of the PMMTI described herein generally resemble those of previous reports, although the present patient was older than most at diagnosis. A subset of PMMTI cases have developed in the trunk, including 5 cases reported within the paraspinal region. 2, 7 Spinal cord compression at presentation has also been previously reported. 1 The present case independently confirms the finding of BCOR ITD in PMMTI, providing key biological insight into the pathogenesis of this rare tumor type. The function of BCOR (BCL-6 corepressor) is to inhibit gene transcription by interacting with BCL-6, histone deacetylase (HDAC), demethylase, and H2A ubiquitin ligase. In addition, BCOR forms a complex with the polycomb group proteins and is a part of the noncanonical PRC1 complex. Based on this interaction, it is assumed that the overexpression and partial duplication of BCOR allows for tumorigenesis via an epigenetic pathway. 5 Other BCOR alterations have been documented in a variety of sarcomas, including mutations found in rhabdomyosarcoma 9 and chromosomal translocations in Ewing-like sarcoma (BCOR-CCND3), 10 ossifying fibromyxoid tumor, and endometrial stromal sarcoma (ZC3H7B-BCOR).
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When feasible, complete resection of PMMTI is the preferred treatment; there are no reports of completely resected PMMTI tumors recurring. As demonstrated in the present case, local recurrences are common after incomplete resections. 7 Most prior patients with incompletely resected tumors were alive with disease (5 of 7), one patient was without evident disease, and one patient was dead of disease at last follow-up.
Few data exist to guide the therapeutic approach for patients with unresectable PMMTI. Given the efficacy and tolerability of vincristine and actinomycin with or without cyclophosphamide (VAC) in infantile fibrosarcoma and embryonal rhabdomyosarcoma that are often encountered in infancy, such therapy would also seem appeal- ing for PMMTI. However, in addition to the present case treated with VA, 3 prior patients treated with VAC were reported to not respond, hence neither VAC nor VA can be considered effective for PMMTI based on currently available information. [12] [13] [14] The use of ifosfamide and doxorubicin has been reported in 2 previous cases, with 1 partial response and 1 disease progression. 12, 13 Given the biological overlap between PMMTI and CCSK, treatment regimens used for CCSK may provide a template for PMMTI therapy. The role of doxorubicin-containing chemotherapy in CCSK is well established, 15 and the Children's Oncology Group recently completed a trial using vincristine, doxorubicin, cyclophosphamide, and etoposide with RT for CCSK (ClinicalTrials.gov identifier: NCT00002611). Hence, the use of VDC/IE as was used successfully in the present case or a similar regimen is worthy of further investigation in PMMTI. As the role of BCOR in malignant transformation is further elucidated, we anticipate that neoplasms driven by BCOR alterations will be found to be amenable to rationally designed targeted therapies. 16 Yet, although the patient responded well to this regimen and only experienced commonly expected toxicities, the potential for cardiomyopathy, secondary cancers, and infertility is significant and must be taken into consideration. Likewise, RT carries potentially dramatic morbidity in infants, but may be Molecular testing and biosimilars offer the potential for increased access to targeted treatment options and reduction in health care costs but come with significant challenges in ensuring patient access to innovation in cancer care while maintaining safe, effective, ethical, and affordable treatment options.
In September 2016, NCCN hosted the Molecular Testing and Biosimilars Policy Summit to address the challenges, issues, and opportunities in both the molecular testing and biosimilar landscapes. 
